CJC-1295 + Ipamorelin Blend

This blend pairs CJC-1295, a long-acting GHRH analog, with ipamorelin, a selective ghrelin-receptor agonist, combining two distinct signaling pathways that converge on the same pituitary growth hormone-releasing cells.

Endocrine research on combining GHRH analogs with ghrelin-receptor agonists has repeatedly found that co-administration produces synergistic, greater than additive growth hormone release compared with either compound given alone.

This synergy rationale is why the combination is used in research aiming to model more robust activation of the GH/IGF-1 axis.